<DOC>
	<DOC>NCT01754142</DOC>
	<brief_summary>The purpose of this post-marketing surveillance is to investigate and confirm the type and incidence of newly identified adverse events and any other factors affecting safety and efficacy of Kombiglyze Extended release (XR) so that the regulatory authority can manage the marketing approval properly</brief_summary>
	<brief_title>Korean Post-marketing Surveillance for Kombiglyze XR®</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. ≥ 18 years of age Have diagnosed Type 2 diabetes mellitus (T2DM) Are initiating Kombiglyze XR treatment within the approved Korean indications Being treated for an indication not approved for the use of Kombiglyze XR in Korea Is contraindicated for the use of Kombiglyze XR as described in the Korean label</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>